JP2018500387A - 抗菌化合物 - Google Patents

抗菌化合物 Download PDF

Info

Publication number
JP2018500387A
JP2018500387A JP2017545516A JP2017545516A JP2018500387A JP 2018500387 A JP2018500387 A JP 2018500387A JP 2017545516 A JP2017545516 A JP 2017545516A JP 2017545516 A JP2017545516 A JP 2017545516A JP 2018500387 A JP2018500387 A JP 2018500387A
Authority
JP
Japan
Prior art keywords
compound
salicylamide
niclosamide
salicylamide compound
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500387A5 (enExample
Inventor
コップ，ジャニン・ナオミ
アッカーリー，デイビッド・フランシス
Original Assignee
ヴィクトリア・リンク・リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィクトリア・リンク・リミティド filed Critical ヴィクトリア・リンク・リミティド
Publication of JP2018500387A publication Critical patent/JP2018500387A/ja
Publication of JP2018500387A5 publication Critical patent/JP2018500387A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017545516A 2014-11-17 2015-11-17 抗菌化合物 Pending JP2018500387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ70200114 2014-11-17
NZ702001 2014-11-17
PCT/NZ2015/050192 WO2016080846A1 (en) 2014-11-17 2015-11-17 Antibacterial compounds

Publications (2)

Publication Number Publication Date
JP2018500387A true JP2018500387A (ja) 2018-01-11
JP2018500387A5 JP2018500387A5 (enExample) 2018-12-27

Family

ID=56014262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545516A Pending JP2018500387A (ja) 2014-11-17 2015-11-17 抗菌化合物

Country Status (5)

Country Link
US (1) US20190328687A1 (enExample)
EP (1) EP3220919A4 (enExample)
JP (1) JP2018500387A (enExample)
CN (1) CN107635563A (enExample)
WO (1) WO2016080846A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537367A (ja) * 2019-06-19 2022-08-25 キューバイオティクス プロプライアタリー リミティド バイオフィルムの破壊

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2661000T3 (es) 2014-09-12 2018-03-27 Antibiotx A/S Uso antibacteriano de salicilanilidas halogenadas
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
GB201805453D0 (en) * 2018-04-03 2018-05-16 Antibiotx As Novel use
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN108998499A (zh) * 2018-06-05 2018-12-14 上海海洋大学 一种快速测定生物被膜中大肠杆菌对抗生素耐药性的方法
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2020176067A1 (en) 2019-02-25 2020-09-03 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with h. pylori using a halogenated salicylanilide
CN112716944A (zh) * 2021-02-25 2021-04-30 成都大学 硝基咪唑类化合物在制备抑制细菌群体感应的药物中的应用
CN121868275A (zh) * 2026-03-19 2026-04-17 吉林大学 雷琐太尔在制备金黄色葡萄球菌抑制剂中的医用用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086658B2 (ja) * 2000-10-02 2008-05-14 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗菌薬および抗炎症剤としてのナフチルサリチルアニリド
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US7879795B2 (en) * 2004-05-21 2011-02-01 Mpex Pharmaceuticals, Inc. Enhancement of tigecycline potency using efflux pump inhibitors
IN2015MN00408A (enExample) * 2012-07-27 2015-09-04 Antonius Martinus Gustave Bunt

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 1, JPN6019027181, 2001, pages 105 - 116, ISSN: 0004432379 *
JOURNAL OF DEVELOPING DRUGS, vol. 3, no. 2, JPN6019027178, 8 October 2014 (2014-10-08), pages 1000124 - 4, ISSN: 0004432378 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537367A (ja) * 2019-06-19 2022-08-25 キューバイオティクス プロプライアタリー リミティド バイオフィルムの破壊
JP7795917B2 (ja) 2019-06-19 2026-01-08 キューバイオティクス プロプライアタリー リミティド バイオフィルムの破壊

Also Published As

Publication number Publication date
US20190328687A1 (en) 2019-10-31
EP3220919A4 (en) 2018-07-18
CN107635563A (zh) 2018-01-26
WO2016080846A1 (en) 2016-05-26
EP3220919A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
US20190328687A1 (en) Antibacterial Compounds
Tehrani et al. Thiol-containing metallo-β-lactamase inhibitors resensitize resistant gram-negative bacteria to meropenem
Wang et al. Antibacterial diamines targeting bacterial membranes
US12469580B2 (en) In silico discovery of effective antimicrobials
Brak et al. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy
US10807943B2 (en) Non-lactone carbocyclic modulators of bacterial quorum sensing
Seferyan et al. Multicationic quaternary ammonium compounds: a framework for combating bacterial resistance
Kany et al. Tackling Pseudomonas aeruginosa virulence by a hydroxamic acid-based LasB inhibitor
US10322112B2 (en) Compound combinations for attenuation of bacterial virulence
JP6142076B2 (ja) 抗微生物性増強剤
JP5898061B2 (ja) 細菌のｉｉｉ型分泌系の阻害剤
Roy et al. Development and antibacterial properties of 4-[4-(anilinomethyl)-3-phenylpyrazol-1-yl] benzoic acid derivatives as fatty acid biosynthesis inhibitors
Zhang et al. Hybrid molecules of benzothiazole and hydroxamic acid as dual-acting biofilm inhibitors with antibacterial synergistic effect against Pseudomonas aeruginosa infections
CA3024561A1 (en) Antibacterial compositions
KR101369584B1 (ko) 페닐-이속사졸 유도체 및 그의 제조방법
JP2015523997A (ja) 微生物バイオフィルム破壊のためのクルクミン誘導体
US20200405691A1 (en) Methods to control infection using new generation small molecule growth inhibitors
Holly et al. Hit-to-Lead optimization of Acetazolamide-Based bacterial carbonic anhydrase inhibitors with efficacy in vivo for treatment of Vancomycin-Resistant enterococci septicemia
US11040949B2 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
US20170267632A1 (en) Methionine analogs and methods of using same
US9604946B2 (en) Methods for modulating bacterial virulence and related compounds
Chakraborty et al. Way of administrating supramolecular drug associates against multidrug-resistant bacteria in improving multidrug therapy
US20230278971A1 (en) Compounds affecting pigment production and methods for treatment of bacterial diseases
CN112351973A (zh) 作为抗生物膜制剂的取代的2-氨基苯并咪唑类似物
WO2024011227A1 (en) Compounds and methods for inhibition of the evolution of antibiotic resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210126